Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
Forward-Looking Statements
This presentation contains forward-looking statements, including, but not limited to, statements related to Horizon's expected financial performance and
operating results in future periods, including potential growth in net sales of certain of Horizon's medicines; development plans; expected timing of clinical trials,
studies and regulatory submissions; potential market opportunity for and benefits of Horizon's medicines and medicine candidates; and business and other
statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks
and uncertainties, which include, without limitation, risks that Horizon's actual future financial and operating results may differ from its expectations or goals;
Horizon's ability to grow net sales from existing medicines; the availability of coverage and adequate reimbursement and pricing from government and third-party
payers; risks relating to Horizon's ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates, and existing
medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including
potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the
legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in
Horizon's filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a
result of new information.
HORIZON
2View entire presentation